Vvax001 is a clinically validated, T-cell–priming immunotherapy based on a self-amplifying RNA (saRNA) replicon delivered by a replication-incompetent Semliki Forest virus (SFV) vector.
Unlike conventional mRNA vaccines, which deliver a single, non-replicating mRNA via lipid nanoparticles, Vvax001 delivers an alphavirus replicon RNA that encodes both the HPV16 E6/E7 tumor antigens and a viral replicase.
Once inside the cell, the replicase enables intracellular amplification of the RNA, resulting in markedly higher and sustained antigen expression compared with standard mRNA. This high antigen load, combined with innate immune activation that mimics viral infection, drives a strong cytotoxic T-cell response. The infected cells undergo apoptosis, and antigen-rich apoptotic bodies are taken up by dendritic cells, further enhancing T-cell priming.
Critically, the SFV vector is engineered to be replication-incompetent: it can enter cells but cannot generate new viral particles or spread. Clinically, Vvax001 has demonstrated a favorable safety profile in Phase I/II studies in HPV16-positive CIN3/HSIL, positioning it as a potent, contained, RNA-based cancer immunotherapy distinct from both conventional mRNA vaccines and replicating viral vectors.
- Vvax001 has a very favorable biosafety profile
- Vvax001 induces high-level antigen expression
- after 48-72 hours of protein expression, the infected SFV cells die by apoptosis resulting in apoptotic bodies containing high levels of the recombinant protein
- Vvax001 activates both the innate and the adaptive immune system
- since SFV is a rodent virus, humans in general do not carry neutralizing antibodies against the virus that may decrease the efficacy of the immunization
|
